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Abstract
Background: Liver surgery for perihilar cholangiocarcinoma (PHC) is associated with high rates of
morbidity and mortality.
Objectives: This study investigated the impact of low skeletal muscle mass on short- and longterm
outcomes following hepatectomy for PHC.
Methods: Patients included underwent liver surgery for PHC between 1998 and 2013. Total skeletal
muscle mass was measured at the level of the third lumbar vertebra using available preoperative
computed tomography images. Sex-specific cut-offs for low skeletal muscle mass were determined by
optimal stratification.
Results: In 100 patients, low skeletal muscle mass was present in 42 (42.0%) subjects. The rate of
postoperative complications (Clavien–Dindo Grade III and higher) was greater in patients with low skel-
etal muscle mass (66.7% versus 48.3%; multivariable adjusted P = 0.070). Incidences of sepsis (28.6%
versus 5.2%) and liver failure (35.7% versus 15.5%) were increased in patients with low skeletal
muscle mass. In addition, 90-day mortality was associated with low skeletal muscle mass in univariate
analysis (28.6% versus 8.6%; P = 0.009). Median overall survival was shorter in patients with low
muscle mass (22.8 months versus 47.5 months; P = 0.014). On multivariable analysis, low skeletal
muscle mass remained a significant prognostic factor (hazard ratio 2.02; P = 0.020).
Conclusions: Low skeletal muscle mass has a negative impact on postoperative mortality and overall
survival following resection of PHC and should therefore be considered in preoperative risk assessment.
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Introduction
Low skeletal muscle mass has been associated with worse out-
comes following surgery for malignancies of gastrointestinal
origin.1–5 It has been shown to affect postoperative morbidity
and mortality in patients with colorectal liver metastases
(CRLM),3 hepatocellular carcinoma (HCC)6 and colorectal
cancer,4 and to impact on longterm survival following resec-
tion of HCC,1,6 pancreatic cancer2 and CRLM.5 In these stud-
ies, low or high body mass index (BMI) was not a risk factor
for poor outcomes. These results suggest that lower skeletal
muscle mass may reflect frailty and may be a highly relevant
factor in preoperative risk assessment. Measurement of the
total skeletal muscle area at the third lumbar vertebra on com-
puted tomography (CT) images has been widely accepted as a
standard method of determining whole-body skeletal muscle
mass in the preoperative workup.7–9
Perihilar cholangiocarcinoma (PHC) is a biliary tumour
located at the liver hilum, which typically requires a combined
extrahepatic bile duct and liver resection in instances of resect-
able disease. Several studies have shown that an aggressive
surgical approach has improved the negative-margin (R0)
resection rate and survival.10,11 However, liver resection in
PHC is associated with high levels of risk for morbidity and
mortality, reported to reach 68% and 14%, respectively.10–13
The identification of potentially reversible risk factors might
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facilitate the preoperative modification of these risks. The aim
of this study was to investigate the impact of low skeletal
muscle mass on postoperative morbidity, mortality and overall
survival following resection of PHC.
Materials and methods
Data were retrospectively collected from a database including
all patients submitted to exploratory laparotomy for PHC
between 1998 and 2013 in a single institution (Academic Medi-
cal Centre, Amsterdam). Inclusion criteria required patients to
have undergone curative-intent major hepatectomy and neces-
sitated the availability of adequate preoperative CT images of
the abdomen. The latter are necessary for skeletal muscle mass
measurement. Study variables included patient characteristics,
laboratory results, tumour characteristics (Bismuth–Corlette
classification and histopathological information), details of
surgery, complications, and overall survival and recurrence
data.
Preoperative measurement of skeletal muscle mass
In all patients, CT scans selected for analysis were performed
after adequate preoperative biliary drainage (if indicated) had
been achieved as part of the routine preoperative workup.
Cross-sectional skeletal muscle surface (cm2) was assessed at
the level of the third lumbar vertebra (L3) on two consecutive
axial slices with visible vertebral spine, as previously
described.14 Plain images were selected by an experienced staff
radiologist (CYN) and measurements were obtained using
OsiriX Version 5.8 (32-bit; http://www.osirix-viewer.com) by
one of the authors (RJSC). Using a Hounsfield units (HU)
range of 30 HU to +110 HU to distinguish skeletal muscle
tissue, measurements of the psoas, paraspinal, transverse
abdominal, internal and external oblique and rectus abdominis
muscles were obtained (Fig. 1). Cross-sectional areas of the
two L3 levels were then averaged and corrected for height to
calculate the L3 muscle index expressed in cm2/m2. A previous
study has demonstrated very good inter-observer variability.4
Weight loss was calculated by subtracting the patient’s
weight at the time of diagnosis from his or her reported weight
prior to illness. The presence of weight loss was then defined
as a >2% loss from pre-illness self-reported stable weight.7
Surgical procedures
Prior to surgery, patients underwent endoscopic biliary drainage
and/or percutaneous drainage when indicated because of jaun-
dice and dilatation of the bile ducts in the future remnant liver.
Preoperative liver function was assessed with CT volumetry and
99mTc-mebrofenin hepatobiliary scintigraphy.15 Patients under-
went radical resection of the tumour encompassing hilar resec-
tion with en bloc (extended) hemi-hepatectomy including the
caudate lobe, excision of the portal vein bifurcation when
involved and complete lymphadenectomy of the hepatoduodenal
ligament in the majority of cases. For biliary reconstruction,
end-to-side anastomoses of the segmental ducts and a Roux-
en-Y jejunal loop were constructed.10 Resections were performed
by two staff surgeons with extensive hepatobiliary expertise.
Definitions of complications
Postoperative morbidity was defined as any severe complica-
tion (i.e. Clavien–Dindo Grade III or higher16) within 30 days
after surgery. Overall complications were further stratified into
postoperative haemorrhage, anastomotic leakage, intra-abdomi-
nal abscess or fluid collections, and acute liver failure, using
previously described definitions. Haemorrhage was defined as a
drop in haemoglobin level of >3 g/dl after the end of surgery
compared with the postoperative baseline level and/or any
postoperative transfusion of packed red blood cells for a falling
haemoglobin level and/or the need for invasive re-intervention
(e.g. embolization or re-laparotomy) to stop bleeding.17 Anas-
tomotic leakage was defined as fluid with an increased biliru-
bin concentration in the abdominal drain (three times greater
than serum bilirubin concentration) on or after postoperative
day (PoD) 3 or the need for radiologic intervention because of
contrast leakage during percutaneous transhepatic cholangiog-
raphy (in the event of hepaticojejunostomy leakage)18 or a
defect of the intestinal wall at the anastomotic site leading to a
communication between the intra- and extraluminal compart-
ments (in the event of enteroenterostomy leakage).19 Sepsis
was defined as the presence (probable or documented) of
infection together with systemic manifestations of infection.20
Intra-abdominal abscess or fluid collection were defined as the
collection of pus or infected fluid inside the abdomen diag-
nosed by CT and treated by percutaneous drainage or surgery.
Acute liver failure was defined as an increasing international
normalized ratio (INR) value (or need of clotting factors to
maintain normal INR) and increasing plasma bilirubin level on
or after PoD 5, impacting clinical management [International
Study Group of Liver Surgery (ISGLS) grade B or higher].21
Postoperative mortality was defined as death within 90 days
after surgery or within the same hospital admission.
Figure 1 Computed tomography scans at the third lumbar
vertebra level of a male patient with normal skeletal muscle mass
(left, L3 muscle index 60.04 cm2/m2) and low muscle mass (right,
L3 muscle index 39.19 cm2/m2). Skeletal muscle area highlighted
in red. 1, rectus abdominis; 2, external oblique; 3, internal oblique;
4, transverse abdominal; 5, psoas; 6, paraspinal.
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Follow-up
No adjuvant chemotherapy was administered after initial
curative resection. Clinical follow-up was performed routinely
every 3 months in the first year after surgery and every
6 months throughout the following 5 years. Laboratory tests
and follow-up CT scans were performed in the first 6
months to detect early recurrence and later as indicated. The
overall survival status of patients discharged from further fol-
low-up was examined by checking the municipal records
database.
Statistical analysis
The variable of skeletal muscle mass was dichotomized using
optimal stratification to allow for risk classification and the
clinical interpretation of effect measures. Optimal stratification
is the preferred method for dichotomizing continuous vari-
ables, as tertiles, quartiles and means lack sufficient sensitivity
to allow the assessment of a variable’s true prognostic value.22
Optimal stratification is a statistical method similar to receiver
operator curve analysis and is able to find the most significant
cut-off for a continuous variable with respect to survival, based
on log rank statistics.22 Sex-specific cut-offs were determined
for the L3 muscle index, and these cut-offs were subsequently
used to categorize patients into low skeletal muscle mass and
normal skeletal muscle mass groups.
Univariate analyses for overall morbidity and mortality
consisted of Pearson’s chi-squared test or Fisher’s exact test
for categorical variables, and the unpaired t-test or Mann–
Whitney U-test for continuous variables. Overall survival,
defined as the number of days of survival after hepatectomy,
was analysed in univariate analysis using a Kaplan–Meier sur-
vival plot, and compared using the log rank test. To further
assess the effect of low skeletal muscle mass, multivariable
analysis was performed for postoperative morbidity (logistic
regression) and overall survival (Cox proportional hazards
model). Multivariable analysis for postoperative morbidity
was used to adjust for known predictors, which were age,
preoperative bilirubin level, hepatectomy side and periopera-
tive blood transfusion.23,24 Multivariable analysis for overall
survival was used to adjust for age, sex, American Society of
Anesthesiologists (ASA) class and known predictors (resection
margin status, lymph node status, tumour differentiation and
postoperative morbidity).11,25 In addition, backward variable
selection was performed on the full model based on variables
with a P-value of <0.05 (variable selection model). Because of
the estimated low number of events (<10 events per variable),
a multivariable analysis of postoperative mortality was not
considered feasible.26 Statistical analysis was performed using
R Version 3.0.3 (R Foundation for Statistical Computing,
Vienna, Austria), and IBM SPSS Statistics for Windows Ver-
sion 20.0 (IBM Corp., Armonk, NY, USA). Two-tailed P-val-
ues of <0.05 were considered to indicate statistical
significance.
Results
A total of 129 patients were identified as having undergone
major hepatectomy for PHC during the study period. In 29
patients (22.5%) no adequate preoperative staging CT scan for
skeletal muscle mass assessment was available in the radiology
information system. In this group of patients, the abdomen had
not been scanned through the L3 level, CT scans could not be
retrieved from the system or staging had been performed using
other imaging modalities such as magnetic resonance imaging.
These cases were therefore excluded from further analysis (Table
S1, online). Of the 100 remaining patients, 64 (64.0%) were male
and 36 (36.0%) were female. Mean  standard deviation (SD)
L3 muscle indices were 47.65  6.38 cm2/m2 in males and 40.74
 6.49 cm2/m2 in females (P < 0.001).
Low and normal skeletal muscle mass groups
Sex-specific cut-off values for L3 muscle mass indices were deter-
mined at 46.8 cm2/m2 for males and 39.1 cm2/m2 for females.
Using these cut-offs, 42 patients (42.0%) were identified as hav-
ing low skeletal muscle mass. The time interval between muscle
mass measurements on CT and surgery did not differ between
the low and normal skeletal muscle mass groups (median: 39
days versus 42 days; P = 0.610). The clinicopathological charac-
teristics of patients in both groups are listed in Table 1. Lower
BMI was observed in patients with low skeletal muscle mass. The
majority of patients with low muscle mass were of normal
weight. Only four of 42 (9.5%) patients with low muscle mass
were defined as cachectic and none of the patients with normal
muscle mass fulfilled these criteria.7 Seventeen patients in the
cohort (17.0%) were identified as overweight or obese (BMI
≥25 kg/m2) and as having low muscle mass. Other preoperative
patient characteristics did not differ between patients with,
respectively, low and normal skeletal muscle mass. Furthermore,
there were no significant differences between the groups in prog-
nostic tumour-related factors.
Postoperative morbidity
Overall complications (Clavien–Dindo Grade III and higher) in
the 30-day postoperative period or during the hospital stay
showed a trend towards a higher incidence in patients with low
skeletal muscle mass (n = 28, 66.7%) compared with patients
with normal muscle mass (n = 28, 48.3%) (P = 0.067). An over-
view of postoperative complications is shown in Table 2. Inci-
dences of sepsis (or septic shock) and liver failure (ISGLS grade
B or higher) differed between the patient groups. A total of 15
patients developed sepsis (or septic shock) in the postoperative
period; these included three patients (5.2%) in the normal mus-
cle mass group and 12 patients (28.6%) in the low muscle mass
group (P = 0.002). Twenty-four patients developed liver failure
(ISGLS grade B or higher), including nine patients (15.5%) in
the normal skeletal muscle mass group and 15 (35.7%) in the
low muscle mass group (P = 0.020). On multivariable analysis,
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low skeletal muscle mass showed an association with postopera-
tive morbidity of borderline significance (P = 0.070) (Table 3).
Because of the low number of events, multivariable analysis for
the risk factors of sepsis and liver failure was not considered to
be feasible.
Postoperative mortality
Seventeen patients (17.0%) in the selected cohort died within
the 90-day postoperative period or during the index hospital
stay. Ninety-day postoperative mortality was higher among
patients with low skeletal muscle mass (28.6% versus 8.6%;
Table 1 Clinicopathological characteristics in patients with low and normal skeletal muscle mass submitted to resection of perihilar
cholangiocarcinoma, using cut-off values obtained by optimal stratification
Normal skeletal muscle
mass (n = 58)
Low skeletal muscle
mass (n = 42)
P-value
Age, years, mean  SD 62  9 61  11 0.520a
Sex ratio, M:F, n:n 36:22 28:14 0.636
BMI, kg/m2, mean  SD 26  3 24  3 0.001a
Weight loss, n (%) 36 (62.1%) 23 (54.8%) 0.463
Jaundice, n (%) 39 (67.2%) 31 (73.8%) 0.367
Diabetes, n (%) 6 (10.3%) 4 (9.5%) 0.893
CA19-9, kU/l, median (range) 176 (1–1363) 98 (16–482) 0.424b
Albumin, g/l, mean  SD 39  5 37  6 0.081a
CRP, mg/l, median (range) 11 (2–269) 17 (1–300) 0.276b
Haemoglobin, mmol/l, mean  SD 8.2  0.9 8.0  0.9 0.228a
Total bilirubin, lmol/l, median (range) 10 (4–48) 18 (4–57) 0.069b
Platelet count, 9109/l, mean  SD 321  105 325  96 0.864a
Preoperative cholangitis, n (%) 20 (34.5%) 20 (50.0%) 0.125
Tumour size, cm, median (range) 2.6 (0.9–12.5) 2.6 (1.3–7.0) 0.978b
Tumour classification, n (%)
BC 1 1 (1.7%) 0 0.844
BC 2 4 (6.9%) 2 (4.8%)
BC 3a 19 (32.8%) 18 (42.9%)
BC 3b 14 (24.1%) 9 (21.4%)
BC 4 12 (20.7%) 9 (21.4%)
Left or right hepatic duct 8 (13.8%) 4 (9.5%)
ASA class, n (%)
0–2 51 (87.9%) 36 (85.7%) 0.745
3, 4 7 (12.1%) 6 (14.3%)
Left:right (extended) hemi-hepatectomy ratioc, n:n 28:29 20:21 0.973
TNM stage, n (%)
0–II 24 (41.4%) 19 (45.2%) 0.700
III, IV 34 (58.6%) 23 (54.8%)
N1 status, n (%) 13 (22.4%) 12 (28.6%) 0.483
R0 resection, n (%) 40 (69.0%) 32 (76.2%) 0.427
Perineural invasion, n (%) 43 (74.1%) 29 (69.0%) 0.666
Moderate/poor differentiation, n (%) 38 (65.5%) 29 (69.0%) 0.845
Papillary tumour type, n (%) 6 (10.3%) 4 (9.5%) 0.893
aUnpaired t-test.
bMann–Whitney U-test.
cOne patient in the normal muscle mass group and one in the low muscle mass group underwent a central resection.
Statistical tests were performed using the chi-squared test or Fisher’s exact test or as indicated otherwise.
ASA, American Society of Anesthesiologists; BC, Bismuth–Corlette; BMI, body mass index; CA 19-9, cancer antigen 19-9; CRP, C-reactive pro-
tein; N1, positive lymph node; R0, negative margin; SD, standard deviation; TNM, tumour–node–metastasis (stage defined by 7th edition of Amer-
ican Joint Committee on Cancer).
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P = 0.009). Other factors associated with postoperative death
in univariate analysis were age of >65 years (P = 0.022) and
perioperative blood transfusion (P < 0.001) (Table 4). Because
of the low number of events, multivariable analysis was not
considered possible. Among patients with low muscle mass,
those who died within the 90-day postoperative period were
older (median age: 67 years versus 61 years; P = 0.029) and had
higher rates of preoperative cholangitis (83.3% versus 35.7%;
P = 0.014) and perioperative blood transfusion (100% versus
63.3%; P = 0.018). Further, a trend towards more extended
hepatectomies (66.7% versus 37.7%; P = 0.098) was noted in
these patients.
Survival
Median follow-up among patients who were alive at follow-up
was 28 months (range: 2–122 months). The median overall
survival of the total cohort was 36.7 months. Overall survival
was shorter in the low skeletal muscle mass group in univariate
analysis (22.8 months versus 47.5 months; P = 0.014) (Fig. 2).
Table 2 Postoperative complications (Clavien–Dindo Grade III and
higher) in the low and normal skeletal muscle mass groups
Normal
skeletal
muscle
mass
(n = 58)
Low
skeletal
muscle
mass
(n = 42)
P-value
Any complication Clavien–
Dindo Grade III+
28 (48.3%) 28 (66.7%) 0.067
Sepsis 3 (5.2%) 12 (28.6%) 0.002
Acute liver failure
(ISGLS grade B+)
9 (15.5%) 15 (35.7%) 0.020
Haemorrhage 6 (10.3%) 2 (4.8%) 0.462
Anastomotic leakage 11 (19.0%) 8 (19.0%) 0.992
Abscess/fluid collection 13 (22.4%) 12 (28.6%) 0.483
Statistical tests were performed using the chi-squared test or Fisher’s
exact test.
ISGLS, International Study group of Liver Surgery.
Table 3 Univariate and multivariable analysis for risk factors of
postoperative morbidity
Univariate analysis Multivariable analysis
Morbidity
rate, n (%)
P-value OR (95% CI) P-value
Low skeletal muscle mass
No 28/58 (48.3%) 0.067 1 (reference) 0.070
Yes 28/42 (66.7%) 2.36 (0.93–5.96)
Age N/A 1.01 (0.97–1.06) 0.592
Preoperative
bilirubin
N/A 1.00 (0.97–1.06) 0.978
Hepatectomy sidea
Left 25/48 (52.1%) 0.556 1 (reference) 0.720
Right 29/50 (58.0%)
Perioperative blood transfusion
No 16/38 (42.1%) 0.028 1 (reference) 0.061
Yes 40/62 (64.5%) 2.70 (0.96–7.62)
aTwo patients underwent a central liver resection.
Univariate analysis was performed using the chi-squared test or Fish-
er’s exact test.
95% CI, 95% confidence interval; N/A, not applicable; OR, odds ratio.
Table 4 Univariate analysis for risk factors for 90-day/in-hospital
mortality
Mortality, n (%) P-value
Low skeletal muscle mass
No 5/58 (8.6%) 0.009
Yes 12/42 (28.6%)
Age >65 years
No 6/60 (10.0%) 0.022
Yes 11/40 (27.5%)
ASA class
0–2 14/87 (16.1%) 0.532
3, 4 3/13 (23.1%)
Hepatectomy side
Left 5/48 (10.4%) 0.076
Right 12/50 (24.0%)
Extended hemi-hepatectomya
No 6/48 (12.5%) 0.250
Yes 11/52 (21.2%)
Perioperative blood transfusion
No 0/38 <0.001
Yes 16/62 (25.8%)
aTwo patients underwent a central liver resection.
Statistical tests were performed using the chi-squared test or Fisher’s
exact test.
ASA, American Society of Anesthesiologists.
Figure 2 Overall survival after resection of perihilar carcinoma in
patients with low (n = 42) and normal (n = 58) skeletal muscle mass
HPB 2015, 17, 520–528 ª 2015 International Hepato-Pancreato-Biliary Association
524 HPB
Corresponding estimated 5-year survival rates in the low and
normal skeletal muscle mass groups were 20.3% and 36.2%,
respectively. Disease recurrence was noted in 34 patients
(34.0%). Median disease-free survival did not differ between
patients with, respectively, low and normal skeletal muscle
mass (43.3 months versus 39.8 months; P = 0.748).
After adjustment for potential and known predictors of sur-
vival in multivariable analysis, low skeletal muscle mass
remained independently associated with poor overall survival
[adjusted hazard ratio (HR) 2.02, 95% confidence interval (CI)
1.12–3.65; P = 0.020] (Table 5). When postoperative deaths
were excluded, low muscle mass was still an independent
predictor of worse survival (HR 2.02, 95% CI 1.04–3.92;
P = 0.037). The combination of low muscle mass and overweight/
obesity was not independently associated with poor survival.
Discussion
The present study shows that low skeletal muscle mass, as
defined by a cholangiocarcinoma-specific cut-off, was present
in 42.0% of patients with resectable PHC. Low skeletal muscle
mass was associated with postoperative sepsis and liver failure,
90-day mortality and overall survival after major liver resec-
tion.
Low skeletal muscle mass has been recognized as a predictor
of postoperative morbidity and mortality in liver transplanta-
tion, as well as in several other gastrointestinal cancers, includ-
ing HCC,1,6 CRLM3,5 and pancreatic carcinoma.2 Previous
studies have related low muscle mass to an increased rate of
postoperative infectious complications, including sepsis and
wound infections.27–29 Reisinger et al. assessed the combined
effect of low skeletal muscle mass and a lower nutritional and
frailty status, and confirmed an associated risk for sepsis.4 High
expression of proinflammatory cytokines [e.g. interleukin-1b
(IL-1b) and IL-6] in low skeletal muscle mass and cancer
cachexia may induce this proinflammatory state and may
increase the risk for infectious complications.30 Septic compli-
cations are of particular relevance in patients with PHC, as
concomitant biliary obstruction predisposes patients to cholan-
gitis and secondary infections. Similarly to studies in colorectal
cancer and liver transplantation for benign disease, the present
authors observed a higher rate of septic complications (28.6%
in patients with low muscle mass versus 5.2% in patients with
normal muscle mass) after liver resection for PHC. An associa-
tion between lower muscle mass and infectious complications
was further suggested by a higher rate of preoperative cholan-
gitis of borderline significance. Nonetheless, the temporal
sequence of this association remains uncertain: cholangitis may
have caused muscle wasting, or patients with lower muscle
mass may be at higher risk for preoperative cholangitis.
Furthermore, a higher rate of postoperative liver failure was
observed in the low muscle mass group (35.7% versus 15.5%).
Overall, skeletal muscle mass showed an association with mor-
bidity of only borderline significance, which may be partly
explained by a lack of sufficient statistical power. Skeletal mus-
cle mass showed a significant association with postoperative
90-day mortality in univariate analysis, although the statistical
power of the present data may be insufficient to confirm this
result in multivariable analysis. Nonetheless, these results war-
rant the assessment of low skeletal muscle mass as a risk factor
prior to liver surgery in PHC.
The negative impact of low skeletal muscle mass on survival
following surgery has also been shown in other hepatobiliary
diseases, including HCC.1,6 The present study found an effect
on survival after liver resection for PHC that was comparable
with the effects of resection margin status, lymph node status
and tumour differentiation grade. The majority of patients
with lower muscle mass did not meet the defined criteria for
Table 5 Univariate and multivariable analysis of clinicopathological factors and overall survival
Univariate analysis Multivariable analysis
Full modela Variable selectionb
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Age 1.00 (0.97–1.03) 0.870 1.00 (0.97–1.03) 0.771 – –
Male sex 1.70 (0.97–2.98) 0.065 1.41 (0.76–2.63) 0.281 – –
ASA class 0.94 (0.58–1.50) 0.783 0.98 (0.55–1.73) 0.933 – –
Low skeletal muscle mass 1.90 (1.13–3.19) 0.015 2.02 (1.12–3.65) 0.020 2.01 (1.14–3.54) 0.016
R1 status 1.89 (1.07–3.33) 0.028 1.88 (0.96–3.67) 0.064 2.06 (1.08–3.91) 0.028
N1 status 1.82 (1.03–3.22) 0.040 1.77 (0.95–3.30) 0.072 1.83 (0.99–3.39) 0.056
Moderate/poor differentiation 2.08 (1.03–4.20) 0.041 2.43 (1.20–4.93) 0.014 2.40 (1.19–4.84) 0.015
Postoperative complications 1.70 (1.00–2.87) 0.049 1.47 (0.78–2.78) 0.234 1.42 (0.77–2.62) 0.261
aCox proportional hazards regression analysis for all factors.
bCox proportional hazards regression analysis after backward variable selection.
95% CI, 95% confidence interval; ASA, American Society of Anesthesiologists; BMI, body mass index; HR, hazard ratio; N1, positive lymph node;
R1, positive margin; TNM, tumour–node–metastasis.
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cancer cachexia, but were simply individuals who had demon-
strated lower skeletal muscle mass prior to surgery. Interest-
ingly, even in the absence of severe cancer-related wasting, CT
assessment of skeletal muscle mass showed prognostic value.
These results underscore the importance of this patient-related
factor.
Interest in the assessment of frailty in surgery patients has
increased in recent years. Preoperative frailty scores to evaluate
the general condition of patients have been developed and have
shown associations with postoperative outcomes.31–33 These
scores, however, are mainly based on patient comorbidities
and rarely involve nutritional status, although decreased nutri-
tional intake has been shown to have significant negative
impact on postoperative mortality.4 Some scores include surro-
gates of skeletal muscle mass (anthropometry, weight loss), but
many require additional measurements in patients. However,
as almost 50% of patients with low muscle mass may not have
any weight loss, whether this factor is an adequate surrogate
marker of skeletal muscle mass should be questioned. So far,
no skeletal muscle mass index has been included in frailty
scores. On the basis of the aforementioned studies and the
present results, the current authors propose that skeletal mus-
cle mass should be considered a factor in such scores. Of
course, whether the inclusion of CT-based muscle measure-
ments is as discriminative as current practice protocols remains
to be ascertained. Although some studies have used dual-
energy X-ray absorptiometry to determine muscle mass deple-
tion, the quantification of muscle mass at L3 on CT images is
straightforward and easily reproducible, and CT scans are
usually available in all patients scheduled for surgery.7,9,34
The question of whether skeletal muscle mass can be
increased preoperatively remains. A recent study on outcomes
after liver transplantation in patients with low muscle mass
observed a significant improvement in overall survival with
perioperative nutritional therapy, although skeletal muscle
mass itself was not increased.35 Other studies have focused on
inhibiting catabolic pathways that promote muscle wasting. In
patients with advanced cholangiocarcinoma, the administration
of selumetinib, which is an inhibitor of mitogen-activated pro-
tein/extracellular signal-regulated kinase and IL-6, led to signif-
icant muscle gain in the majority of patients, but no survival
benefit was observed.36 It has been suggested that regular exer-
cise prevents frailty and improves skeletal muscle mass and
physical function in older patients,37 but further studies are
needed to assess the effects of preoperative training on muscle
mass and survival. In general, modulating skeletal muscle mass
seems possible and may therefore represent a promising strat-
egy towards improving postoperative outcomes and even low-
ering health care costs.38
The present study has several limitations. Firstly, the exclusion
from analysis of patients without adequate CT scans has presum-
ably resulted in some degree of selection bias, although the com-
parison of demographics and complications between included
and excluded patients revealed only a clinically significant lower
number of R0 resections in the latter group (Table S1). The pro-
cess of selecting study subjects from a total cohort of patients
with PHC undergoing hepatectomy led to a smaller sample size
and lower number of events. The consequent statistical uncer-
tainty may have particularly influenced the analysis of postoper-
ative morbidity, which showed associations with the analysed
predictors of only borderline significance. Moreover, the even
lower number of events in the analysis of postoperative mortality
prevented the performance of multivariable analysis for that
endpoint. Secondly, the study was designed to use a disease-spe-
cific cut-off for PHC, as others have done previously for various
diseases.5,8 Previously established cut-offs were found to show an
inaccurate fit that would lead to inaccurate effect measurement.
This observation may be explained by the inclusion in the pres-
ent cohort of less overweight patients. Established cut-offs may
not be applicable to all cancer populations as a result of clinico-
pathological differences and the present authors therefore
propose that the optimal stratification method be used to inves-
tigate a relationship between skeletal muscle mass and postoper-
ative outcome in such instances.
Thirdly, a relatively high 90-day mortality rate (17.0%) was
observed in the preselected cohort (especially in individuals
with low muscle mass), given that previous results established
by the present group had shown postoperative mortality of
7–10%. The latter series, however, also included patients
undergoing only local resection of the extrahepatic bile duct.10
The high mortality rate (28.6%) within the low muscle mass
group may have resulted from higher age, the presence of pre-
operative cholangitis and more extensive resections in these
diseased patients.
Finally, as biliary drainage has been shown to increase nutri-
tional status, it may also indirectly influence preoperative skel-
etal muscle mass.39 Standard measurement of skeletal muscle
mass status on post-drainage CT scans ensured the standardi-
zation of the current analysis. However, the effect of biliary
drainage on skeletal muscle mass was not measured because
adequate pre-drainage scans were not available.
To conclude, the present study shows that low skeletal
muscle mass has a negative impact on short- and longterm
outcomes after hepatectomy for PHC. Therefore, measurement
of skeletal muscle mass should be considered in the preopera-
tive risk assessment of patients with PHC. Preoperative ampli-
fication of skeletal muscle mass in patients with low muscle
mass, using nutritional intervention and/or exercise, potentially
improves postoperative outcomes.
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